all report title image

PRECISION MEDICINE DIAGNOSTICS MARKET ANALYSIS

Precision Medicine Diagnostics Market, by Technology (Bioinformatics, Gene Sequencing, Drug Discovery, Precision Molecular Diagnostics, and Big Data Analytics), by application (Oncology, CNS, Hematology, Respiratory, Immunology, and Others), and by Region (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022-2028

  • To Be Published : Sep 2024
  • Code : CMI2422
  • Formats :
      Excel and PDF
  • Industry : Clinical Diagnostic

Precision Medicine Diagnostics MarketSize and Trends

Precision Medicine Diagnostics Market- Drivers

Precision medicine diagnostics market is expected to expand at rapid pace in near future, owing to increasing number of pipeline studies to develop new treatment for cancer. For instance, in January 2016, University of Arkansas initiated the clinical trial for fresh tissue biopsy to study the further advancements in bio-specimens (blood cellular free component, e.g., plasma, serum, tissue, urine), in order to develop precision medicine for lung cancer management and screening (synergy with imaging). Fresh tissue biopsy involves taking a small sample of tissue from the body part for further microscopic examination. The study is estimated to complete in December 2019.

Moreover, government initiatives to create awareness among the community health worker is expected to boost growth of the precision medicine diagnostics market. For instance, in March 2018, the Division of Community Engagement and University of Agricultural and Horticultural Sciences (UAHS) Center for Applied Genetics and Genomic Medicine partnered with the University Of Arizona Banner Health Research Program to develop and implement a unique and culturally conscious approach to increase precision medicine literacy, particularly among underserved and marginalized populations. The program has been named as ‘Precision Medicine Community Health Workers/Promoters for All of Us’.

Furthermore, in October 2017, the National Institutes of Health (NIH) collaborated with 11 biopharmaceutical companies to launch a five-year Accelerating Cancer Therapies (PACT) program, this collaboration is focused on enhancing precision medicine approaches to cancer care. Initial focus of PACT is to identify, develop, and validate robust biomarkers (standardized biological markers) of disease and treatment response, to advance new immunotherapy treatments that controls immune system to attack cancer. The total cost of the project was US$ 215 million.

Need a Custom Report?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports

Customize Now

Want to Buy a Report but have a Limited Budget?

We help clients to procure the report or sections of the report at their budgeted price. Kindly click on the below to avail

Request Discount
Logo

Credibility and Certifications

ESOMAR
DUNS Registered
Clutch
DMCA Protected

9001:2015

Credibility and Certifications

27001:2022

Credibility and Certifications

EXISTING CLIENTELE

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients
trusted clients logo
© 2024 Coherent Market Insights Pvt Ltd. All Rights Reserved.